- Home
- A-Z Publications
- Current Radiopharmaceuticals
- Previous Issues
- Volume 12, Issue 2, 2019
Current Radiopharmaceuticals - Volume 12, Issue 2, 2019
Volume 12, Issue 2, 2019
-
-
Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours
Authors: Vincenzo Cuccurullo, Giuseppe D. Di Stasio and Luigi MansiBackground: Pancreatic Neuroendocrine Tumors (P-NETs) are a challenge in terms of both diagnosis and therapy; morphological studies need to be frequently implemented with nonstandard techniques such as Endoscopic Ultrasounds, Dynamic CT, and functional Magnetic Resonance. Discussion: The role of nuclear medicine, being scarcely sensitive F-18 Fluorodeoxyglucose, is mainly based on the over-expression of So Read More
-
-
-
State of the Art and Recent Developments of Radiopharmaceuticals for Pancreatic Neuroendocrine Tumors Imaging
Authors: Angela Carollo, Stefano Papi, Chiara M. Grana, Luigi Mansi and Marco ChinolBackground: Neuroendocrine Tumors (NETs) are relatively rare tumors, mainly originating from the digestive system, that tend to grow slowly and are often diagnosed when metastasised. Surgery is the sole curative option but is feasible only in a minority of patients. Among them, pancreatic neuroendocrine tumors (pancreatic NETs or pNETs) account for less than 5% of all pancreatic tumors. Viable therapeutic options include Read More
-
-
-
Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours
Authors: Shahad Alsadik, Siraj Yusuf and Adil AL-NahhasBackground: The incidence of pancreatic Neuroendocrine Tumours (pNETs) has increased considerably in the last few decades. The characteristic features of this tumour and the development of new investigative and therapeutic methods had a great impact on its management. Objective: The aim of this review is to investigate the outcome of Peptide Receptor Radionuclide Therapy (PRRT) in the treatment of pancreatic neuroe Read More
-
-
-
Imaging of Pancreatic-Neuroendocrine Tumours: An Outline of Conventional Radiological Techniques
Authors: Muhammad A. Zamir, Wasim Hakim, Siraj Yusuf and Robert ThomasIntroduction: Pancreatic Neuroendocrine Tumours (p-NETs) are an important disease entity and comprise of peptide-secreting tumours often with a functional syndrome. Accounting for a small percentage of all pancreatic tumours, they have a good overall survival rate when diagnosed early, with surgery being curative. The role of nuclear medicine in the diagnosis and treatment of these tumours is evident. However, the vast Read More
-
-
-
Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides?
Authors: Vittorio Briganti, Vincenzo Cuccurullo, Giuseppe D. Di Stasio and Luigi MansiBackground: Pancreatic Neuroendocrine Tumors (PNETs) are rare neoplasms, sporadic or familial, even being part of a syndrome. Their diagnosis is based on symptoms, hormonal disorders or may be fortuitous. The role of Nuclear Medicine is important, mainly because of the possibility of a theranostic strategy. This approach is allowed by the availability of biochemical agents, which may be labeled with radionuclides suitable Read More
-
Volumes & issues
Most Read This Month
Article
content/journals/crp
Journal
10
5
false
en
